Content
03/18/2024
Pleasanton, CA USA
ConKay Medical Systems
completed $1.8 million Seed Round funding. Investors include
SCP Ventures, Unorthodox Ventures.
About
ConKay Medical Systems is an early-stage medical device company advancing unique solutions to treat valvular regurgitation in patients with progressive heart failure. Valvular regurgitation is when your valves do not close properly allowing blood to flow backwards in your heart causing shortness of breath, chest pain, and sometimes death. There are over 100 million people currently affected globally with valvular disease and an additional 5M Americans are diagnosed each year. ConKay’s annular repair technology is designed to treat the main cause of functional regurgitation leaving the healthy leaflets intact to perform the way it was intended. We are currently focused on the Tricuspid valve. Message us for more information!
Startup
Sector:
MedTech
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
